Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study data from P.J. Wysocki and colleagues update understanding of breast cancer
November 6th, 2008
According to recent research from Poznan, Poland, "Docetaxel is a member of the taxoid anticancer agents routinely used in the treatment of high-risk or metastatic breast cancer. A recent study demonstrated that a low response rate to taxane-based neoadjuvant chemotherapy is associated with BRCA1 mutations." "Therefore the frequency of BRCA1 mutations in a population of metastatic docetaxel-refractory patients was analyzed. Nineteen treatment-refractory patients were selected from a group of 175 metastatic breast cancer patients treated with docetaxel-based therapy. DNA isolated from blood or from paraffin-embedded tissue samples was screened for three founder mutations...
Source: Women's Health Weekly (2008-11-06)
|
